7-Oxolithocholic Acid Bulk Price 2026: Market Outlook and Procurement Guide
- Market Forecast: Industrial demand for bile acid intermediates is driving stable bulk price trends into 2026.
- Technical Specs: High industrial purity (≥98%) requires optimized oxidation processes and strict QC.
- Supply Chain: Partnering with a verified global manufacturer ensures consistent CAS 4651-67-6 availability.
The pharmaceutical and biochemical sectors are increasingly relying on specialized bile acid derivatives for metabolic research and therapeutic development. As we approach 2026, the bulk price for 7-Oxolithocholic Acid is influenced by raw material availability, synthesis complexity, and regulatory compliance. Procurement managers must look beyond unit costs to evaluate the total value of supply, including consistency, documentation, and technical support. This analysis provides a detailed overview of cost drivers and technical specifications essential for large-scale sourcing.
Current Market Pricing Trends for 7-Oxolithocholic Acid in Bulk
Forecasting the bulk price of 7-Oxolithocholic Acid for 2026 requires an understanding of the upstream supply chain. The compound, identified by CAS 4651-67-6, is a critical intermediate in the synthesis of ursodeoxycholic acid and other therapeutic bile acids. Pricing volatility is often linked to the cost of precursor steroids and the efficiency of the oxidation steps required to introduce the 7-keto functionality.
While small-scale research quantities command premium pricing due to packaging and handling overheads, industrial bulk procurement offers significant economies of scale. Manufacturers who control the entire synthesis route from basic bile acid extraction to final purification can offer more competitive rates. In 2026, buyers should expect pricing structures that reflect multi-kilogram or ton-scale commitments, with discounts applied for long-term contracts. It is crucial to request detailed quotations that include freight, insurance, and stability testing, as these factors impact the landed cost significantly.
Factors Influencing Industrial-Grade 7-Oxolithocholic Acid Costs
The cost structure of 7-Oxolithocholic Acid is heavily dependent on the achieved purity level and the robustness of the manufacturing process. Research-grade materials may suffice for in vitro assays, but pharmaceutical synthesis demands industrial purity with tightly controlled impurity profiles. The oxidation of the 7-hydroxy group to a ketone must be managed carefully to avoid over-oxidation or epimerization at other chiral centers.
Key cost drivers include:
- Raw Material Sourcing: Availability of high-quality lithocholic acid derivatives.
- Process Efficiency: Yield optimization in the oxidation reaction reduces waste and cost per kilogram.
- Quality Control: Comprehensive testing via HPLC and NMR to verify the 3α-Hydroxy-7-oxo-5β-cholanic Acid structure adds to operational expenses but ensures safety.
- Storage and Logistics: Proper handling, such as shipping with blue ice or at ambient temperature depending on formulation, affects logistics costs.
Manufacturers investing in automated purification systems and strict environmental controls can maintain consistent quality while managing production costs. Buyers should prioritize suppliers who provide a complete Certificate of Analysis (COA) with every batch, detailing residual solvents, heavy metals, and assay potency.
Technical Specifications and Stability Data
Understanding the physicochemical properties of the material is vital for process integration. The following table outlines the standard technical specifications expected for high-quality bulk supply.
| Parameter | Specification |
|---|---|
| Product Name | 7-Oxolithocholic Acid |
| CAS Number | 4651-67-6 |
| Molecular Formula | C24H38O4 |
| Molecular Weight | 390.56 g/mol |
| Purity (HPLC) | ≥ 98.0% (Industrial Grade) |
| Appearance | White to Off-White Powder |
| Solubility | Soluble in DMSO (≥ 100 mg/mL) |
| Storage Condition | Powder: -20°C; Solution: -80°C |
Stability is a critical consideration for long-term storage. The compound should be kept away from moisture to prevent hydrolysis or degradation. For solution preparation, sonication is often recommended to ensure complete dissolution in solvents like DMSO. When scaling up reactions, maintaining these storage conditions ensures the integrity of the material throughout the production cycle.
How to Source Cost-Effective High-Purity 7-Oxolithocholic Acid for Pharmaceutical Synthesis
Sourcing reliable bulk quantities requires partnering with established chemical producers who prioritize transparency and technical excellence. When evaluating potential suppliers, procurement teams should verify the manufacturer's capacity to handle large orders without compromising quality. A reliable global manufacturer will have established logistics networks to ensure timely delivery and compliance with international shipping regulations.
For projects requiring precise stereochemistry and high assay values, verifying the chemical identity is paramount. When sourcing high-purity 3α-Hydroxy-7-keto-5β-cholanic Acid, buyers should request sample batches for internal validation before committing to full-scale production. This step mitigates the risk of process failure due to substandard raw materials.
NINGBO INNO PHARMCHEM CO.,LTD. stands out as a premier partner for such specialized intermediates. With a focus on process chemistry and scalable manufacturing, NINGBO INNO PHARMCHEM CO.,LTD. offers the technical support and supply chain reliability necessary for complex pharmaceutical synthesis. Their commitment to providing detailed technical data and consistent batch-to-bquality makes them a preferred choice for industrial clients looking to secure their supply chain against market fluctuations.
Conclusion
The market for 7-Oxolithocholic Acid is poised for steady growth as applications in metabolic research and drug development expand. By understanding the factors influencing bulk price and prioritizing industrial purity, buyers can secure cost-effective supply contracts for 2026 and beyond. Engaging with a technically proficient supplier ensures that production timelines are met without compromising on the quality of the final therapeutic product.